This molecular synergy becomes especially pronounced when occurring in the context of common genetic alterations characteristic of Type I endometrial carcinoma: PI3K mutations, particularly activating mutations in PIK3CA encoding the catalytic subunit, synergize with PTEN tumor suppressor loss to create a molecular environment where IGF-1 and insulin signaling become pathologically amplified. Here, PTEN is linked to endometrial carcinoma.